Home
News
Create
Screeners
Insights
Gujarat Kidney and Super Speciality
121.
68
-4.02
(-3.20%)
Market Cap
₹959.36 Cr
PE Ratio
74.44
Industry
Healthcare Services
Buy
Sell
Company Performance:
1D
-3.20%
1M
+17.26%
6M
+16.40%
1Y
+16.40%
5Y
+16.40%
View Company Insights
Latest news about Gujarat Kidney and Super Speciality
Gujarat Kidney and Super Speciality Limited Postal Ballot Results: All Resolutions Approved
9 days ago
Gujarat Kidney and Super Speciality Limited shareholders approved all three resolutions through postal ballot on 25-04-2026, including healthcare expansion funding (100% approval), voluntary revision of financial statements under Section 131 (99.9998% approval), and appointment of Mr. Dharmendra Bhaliya as Secretarial Auditor for FY 2025-26 (99.9994% approval). The e-voting process conducted from 27th March to 25th April 2026 achieved 72.1003% participation with 56,846,254 votes cast out of 78,843,250 total shares.
Gujarat Kidney Pays Rs 20,000 Fines to BSE and NSE for Board Meeting Delay
Apr 22, 2026
Gujarat Kidney and Super Speciality Limited Submits SEBI Compliance Certificate for Q4FY26
Apr 07, 2026
Gujarat Kidney Completes Postal Ballot Notice Dispatch for IPO Fund Reallocation
Mar 26, 2026
Gujarat Kidney and Super Speciality Limited Acquires Parekhs Hospital for ₹77 Crore
Mar 23, 2026
More news about Gujarat Kidney and Super Speciality
21
Mar 26
Gujarat Kidney Pays ₹6.61 Lakh Penalty to NSE and BSE for Regulatory Non-Compliance
Gujarat Kidney and Super Speciality Limited has completed payment of regulatory penalties totaling ₹6,60,800 to NSE and BSE for failing to submit quarterly financial results within prescribed timelines. The company paid ₹3,30,400 to each exchange via RTGS on March 20, 2026, following penalty notices received on March 17, 2026, and has formally communicated the settlement to both exchanges.
19
Mar 26
Gujarat Kidney Appoints Auditors and Approves Postal Ballot with Q2 FY25 Results
Gujarat Kidney And Superspeciality Limited conducted a board meeting on March 19, 2026, appointing Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY 2025-26. The board also approved postal ballot notice and ratified Q2 FY25 financial results, which showed consolidated revenue growth of 37.40% to ₹1,292.88 lacs despite a decline in net profit.
13
Mar 26
Gujarat Kidney And Super Speciality Limited Reports Mixed Q2FY26 Results with Revenue Decline
Gujarat Kidney And Super Speciality Limited reported Q2FY26 standalone revenue of ₹964.26 lacs, up 2.47% YoY, but net profit declined 22.17% to ₹230.12 lacs due to rising expenses. Half-year performance showed stronger growth with revenue increasing 12.97% to ₹2,109.25 lacs and net profit rising 10.12% to ₹620.10 lacs. Consolidated results demonstrated significant revenue growth of 37.40% to ₹1,292.88 lacs, reflecting successful expansion through subsidiaries, though profitability remained under pressure with EPS declining across both standalone and consolidated operations.
Gujarat Kidney and Super Speciality
121.
68
-
4.
02
(-
3.
20
%)
1 Year Returns:
+16.40%
Industry Peers
Apollo Hospitals
7,772.00
(+
0.
45
%)
Max Healthcare Institute
1,000.45
(-
1.
10
%)
Fortis Healthcare
949.55
(-
0.
35
%)
Aster DM Healthcare
742.80
(-
0.
28
%)
Narayana Hrudayalaya
1,763.80
(-
1.
69
%)
Global Health
1,170.20
(-
0.
11
%)
Krishna Institute of Medical Sciences
676.40
(-
1.
00
%)
Dr. Agarwal's Health Care
456.65
(+
0.
91
%)
Rainbow Childrens Medicare
1,257.80
(-
0.
23
%)
Park Medi World
239.82
(-
0.
09
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO